Atherosclerosis Therapeutics Market: Introduction

  • Atherosclerosis is the thickening, hardening, and loss of elasticity of the walls of the arteries. It is also known as arteriosclerosis. Atherosclerosis results in plaque formation inside the arteries. Arteries are blood vessels that carry blood from the heart to other parts of the body. Arteries are lined by a thin layer of cells known as endothelium. Atherosclerosis begins with the damage of endothelium due to smoking, high cholesterol, and high blood pressure. That damage leads to the formation of plaque. Plaque is made of calcium, cholesterol, fat, and other substances found in the blood.
  • Accumulation of plaque causes hardening and narrowing of the arteries. Gradually, plaque grows in size and may partially or totally block blood flow and reduce blood flow to organs such as the heart and other parts of your body. This can lead to serious problems including stroke, heart attack, or even death. Atherosclerosis can affect any artery in the body, including arteries in the legs, brain, heart, arms, pelvis, and legs, resulting in the development of different diseases based on which arteries are affected. Atherosclerosis plaques causes three main types of cardiovascular diseases: coronary artery disease, cerebrovascular disease, and peripheral artery disease.
  • Coronary heart disease (CHD) or coronary artery disease is a major cause of death and disability across the world. CHD is responsible for about one-third or more of total deaths in the population over age 35. It is estimated that one-third of middle-aged women and half of all middle-aged men in the U.S. develop some manifestation of coronary heart disease.

Key Drivers, Restraints, and Opportunities of Global Atherosclerosis Therapeutics Market

  • The global atherosclerosis therapeutics market is expected to expand, due to an increase in the geriatric population and rise in the incidence rate of heart attacks due to coronary heart disease or atherosclerosis. Additionally, availability of new treatment approaches (branded and generic) is a key factor driving the global atherosclerosis therapeutics market. According to the Centers for Disease Control and Prevention (CDC), about 610, 000 people from the U.S. died due to heart diseases, which is nearly one in every four deaths. Among heart diseases, coronary artery disease is a highly common heart disease, causing about 370,000 deaths per year. These factors are estimated to boost the global atherosclerosis therapeutics market. However, dependence on symptom-based treatment in several cases and limited efficacy and side-effects of the drugs available in the market are expected to restrain the global atherosclerosis therapeutics market during the forecast period.

North America to Capture Major Share of Global Atherosclerosis Therapeutics Market

In terms of region, the global atherosclerosis therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the global market during the forecast period due to the presence of major players, higher cases of cardiovascular diseases and atherosclerosis, and well-established healthcare infrastructure. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are key factors that are anticipated to boost the market.

The U.S. held a major share of the market in North America due to supportive healthcare policies, a high number of patients, and a developed healthcare market. About 647,000 people in the U.S. die from heart disease every year, i.e., 1 in every 4 deaths. Heart disease costs the U.S. around US$ 219 billion each year. According to statistics, an increase in patient pool and disposable income in this country propels the market of the region.

Key Players Operating in Global Atherosclerosis Therapeutics Market

The atherosclerosis drugs market is moderately competitive and includes major players. Major players operating in the global atherosclerosis therapeutics market are:

  • Pfizer Inc.
  • AstraZeneca
  • Merck & Co., Inc.
  • Sanofi US
  • Amgen Inc.
  • Novartis AG
  • GlaxoSmithKline Plc
  • Bayer AG
  • Mylan N.V.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Isis Pharmaceuticals, Inc.
  • Anthera Pharmaceuticals
  • Johnson and Johnson
  • Cardium Therapeutics
  • The Medicine Company

Global Atherosclerosis Therapeutics Market: Research Scope

Global Atherosclerosis Therapeutics Market, by Drug Treatment

  • Anti-platelet medications
  • Cholesterol lowering medications
  • Beta blockers
  • Angiotensin-converting enzyme (ACE) inhibitors
  • Calcium channel blockers
  • Water pills
  • Others

Global Atherosclerosis Therapeutics Market, by Distribution Channel

  • Drug stores
  • Hospital pharmacies
  • Clinics

Global Atherosclerosis Therapeutics Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.

The scrutiny of the various forces impacting the dynamics of the market, and key and associated industries, guides enterprises in understanding various consumer propositions. Our clients leverage these insights and perspectives to enhance customer experience in the fast-paced business environment.

All our insights and perspectives are broadly based on 4 Pillars or Stages: ASBC-S, which offer an elaborate and customizable framework for the success of an organization. The essence and the roles of these in organizational successes are highlighted below:

  • Agenda for CXOs: TMR, through the study, sets the tone for agendas that are pertinent to CEOs, CFOs, CIOs, and other CXO executives of businesses operating in the market. The perspectives help our clients to bridge the gap between agenda and action plan. TMR strives to offer guidance to CXOs to undertake mission-critical activities empowered by various business analysis tools, and boost the performance of the organizations. The perspectives guide you to decide on your own marketing mix that align well with the policies, visions, and mission.
  • Strategic Frameworks: The study offers how organizations are setting both short-term and long-term strategic plans. Our team of experts collaborate and communicate with you to understand these to make your organizations sustainable and resilient during tough times. The insights help them decide sustainable competitive advantage for each business units.
  • Benchmarking for Deciding Target Markets and Brand Positioning: The assessments in the study provides a scrutiny of marketing channels and marketing mix. Our various teams work synergistically with you to help identify your actual and potential direct, indirect, and budget competition areas. Additionally, the study helps you decide most effective budgets for various processes and promotional activities. Furthermore, the study guides you to set benchmarks for integrating people and processes with the 4Ps of marketing. Eventually, this will empower you to find out unique propositioning strategies and niches.
  • Business Composability for Sustainability (C-S): Constant strategy planning for sustainability characterizing our C-S framework in the report has become more relevant than before in the face of disruptions caused by pandemics, recessions, boom and bust cycles, and changing geopolitical scenario. The TMR study offers a high level of customization to help you achieve business composability. Composable enterprises are increasingly gaining the attention of CXOs in order to help them combat market volatility. Our analysts and industry experts help you wade through such uncertainties and guide you to become a smart sustainable business in entirety.

The study presents scrutiny of region-specific consumer and technology trends, including the most recent industry dynamics. These broadly cover but not limited to

  • North America, South America, and the Americas
  • Asia Pacific and Japan
  • Europe
  • Latin America
  • Middle East and Africa

The study offers data-driven insights and guidance of several aspects. Some of the more notable questions are:

  • What are the major recent trends that can influence the product life cycle and the RoI?
  • Which regulatory trends shape corporate-level, business-level, and functional-level strategies?
  • Which micromarketing initiatives of leading players will bring in investments?
  • What can be the best framework and tools for PESTLE analysis?
  • Which regions will witness rise in new opportunities?
  • Which are the game-changing technologies being used to capture new revenue streams in the near future?
  • Which operational and tactical frameworks are being adopted by various players in gaining customer loyalty?
  • What is the current and expected intensity of competition the market in the near future?

Disclaimer: This market research study is an ongoing effort and extreme care has been taken to maintain the highest levels of accuracy at all stages. However, in the light of the rapidly evolving business dynamics, some region-specific or other segment-specific changes may take time to be part of the study.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

Atherosclerosis Therapeutics Market